Strides Pharma Consolidated June 2022 Net Sales at Rs 940.07 crore, up 36.57% Y-o-Y
July 29, 2022 / 03:11 PM IST
Reported Consolidated quarterly numbers for Strides Pharma Science are:Net Sales at Rs 940.07 crore in June 2022 up 36.57% from Rs. 688.37 crore in June 2021.
Quarterly Net Loss at Rs. 135.89 crore in June 2022 up 33.78% from Rs. 205.20 crore in June 2021.
EBITDA stands at Rs. 73.70 crore in June 2022 up 300.76% from Rs. 36.71 crore in June 2021.
Strides Pharma shares closed at 334.45 on July 28, 2022 (NSE) and has given -15.00% returns over the last 6 months and -54.78% over the last 12 months.
| Strides Pharma Science | | Consolidated Quarterly Results | in Rs. Cr. |
|
| Jun'22 | Mar'22 | Jun'21 | | Net Sales/Income from operations | 940.07 | 866.02 | 688.37 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 940.07 | 866.02 | 688.37 | | EXPENDITURE | | Consumption of Raw Materials | 492.70 | 169.18 | 316.93 | | Purchase of Traded Goods | 59.31 | 117.40 | 60.78 | | Increase/Decrease in Stocks | -80.41 | 140.90 | -28.63 | | Power & Fuel | -- | -- | -- | | Employees Cost | 183.66 | 157.25 | 161.36 | | Depreciation | 60.40 | 60.68 | 54.88 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 224.66 | 239.12 | 228.17 | | P/L Before Other Inc., Int., Excpt. Items & Tax | -0.25 | -18.51 | -105.12 | | Other Income | 13.55 | 86.06 | 13.53 | | P/L Before Int., Excpt. Items & Tax | 13.30 | 67.55 | -91.59 | | Interest | 54.54 | 49.48 | 41.45 | | P/L Before Exceptional Items & Tax | -41.24 | 18.06 | -133.04 | | Exceptional Items | -65.77 | -76.95 | -91.54 | | P/L Before Tax | -107.01 | -58.88 | -224.58 | | Tax | -28.07 | -131.48 | -35.54 | | P/L After Tax from Ordinary Activities | -78.94 | 72.60 | -189.04 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | -78.94 | 72.60 | -189.04 | | Minority Interest | -0.56 | 0.26 | 3.37 | | Share Of P/L Of Associates | -56.39 | -43.64 | -19.53 | | Net P/L After M.I & Associates | -135.89 | 29.22 | -205.20 | | Equity Share Capital | 89.79 | 89.79 | 89.72 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -15.13 | 3.25 | -22.88 | | Diluted EPS | -15.13 | 3.25 | -22.88 | | EPS After Extra Ordinary | | Basic EPS | -15.13 | 3.25 | -22.88 | | Diluted EPS | -15.13 | 3.25 | -22.88 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
